
The Food and Drug Administration granted a priority review to Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for the frontline treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing, according to Roche, the drug’s manufacturer.






